Agenda.
- Provisional Agenda -
Thursday 11th May 2023
1250 - 1300
The Patient Journey
Martin Sweeney
Patient Advocate
1300 - 1320
Men with Prostate Cancer & Their Needs
Prof Suzanne Chambers
Australian Catholic University, Brisbane
1320 - 1340
Evolving Role For Biomarkers and Imaging After Prostate Cancer Diagnosis
Prof Matt Cooperberg
University of Chicago
1340 - 1400
Radiation Oncology - Perspective on TMT in Bladder Cancer
Dr Sophia Kamran
Harvard Medical School
1400 - 1420
Pathology- Molecular Aspects of Urothelial Carcinoma
Dr Priti Lal
University of Pennsylvania
1420 - 1440
Gleason 6 Prostate Cancer- Time To Stop Calling It Cancer?
Prof Scott Eggener
University of California, San Francisco
1440 - 1500
Adjuvant Treatment for Renal Cell Carcinoma – Are Immune Checkpoint Inhibitors the Answer?
Dr Jack Gleeson
Cork University Hospital.
1500 - 1530
Panel Discussion - Renal
1530 - 1600
Coffee Break
1600 - 1620
The Search for Biomarkers to Predict Immunotherapy Response in Renal Cell Carcinoma
Dr Yasser Ged
John Hopkins Hospital, Baltimore
1620 – 1640
Artificial Intelligence in Bladder Cancer
Dr Girish Kulkarni
Princess Margaret Cancer Center, Toronto
1640 - 1700
The Surgical Management of High Risk Prostate Cancer
Prof Prasanna Sooriakumaran
Cleveland Clinic, London
1700 - 1720
Radiation - High Risk Prostate Cancer
Prof Paul Nguyen
Dana-Farber Cancer Institute, Boston
1720 - 1740
The Royal College of Surgeons King James IV Professorship Lecture- Kidney Cancer
Prof Grant Stewart
University Of Cambridge
1740 - 1800
Is Robot Assisted Radical Cystectomy The Standard Of Care?
Prof John Kelly
University College London
1800 – 1830
Panel Discussion- Bladder
1830
End of Day 1
Friday 12th May 2023
0830 - 0840
The Patient Journey
Patient Advocate
0840 - 0900
Using PSMA-PET – Evidence or Philosophy
Mr Thomas Walton
Nottingham City Hospital
0900 - 0920
The Subtypes of Bladder Tumours
Dr Priti Lal
University of Pennsylvania
0920- 0940
Update on Active Surveillance for Prostate Cancer
Prof Matt Cooperberg
University of Chicago
0940 - 1000
Peri-operative Systemic Therapy for Urothelial Carcinoma – State of the Art and Future Avenues
Prof Alison Birtle
Lancashire Teaching Hospitals
1000 - 1020
Development and Validation of a Novel Six-Gene Signature to Predict Aggressive Prostate Cancer
Prof Liam Gallagher
University College Dublin
1020 - 1100
Coffee Break
1100 –1120
Post Prostatectomy Radiation/Salvage Radiation in PSMA Era
Prof Paul Nguyen
Dana-Farber Cancer Institute, Boston
1120 - 1140
IPCOR Study 2023
Mr David Galvin
IPCOR
1140 - 1200
Emotional Toll of Surgical Complications
Prof Scott Eggener
University of California, San Francisco
1200 - 1220
The ANP Role in Non- Muscle Invasive Bladder Cancer
Mr Robert McConkey
University Hospital Galway
1220 - 1240
Novel and Emerging Therapeutic Strategies for Prostate Cancer
Dr Lynda Corrigan
Tallaght University Hospital
1240– 1300
Surgical Treatment of Early Kidney Cancer
Prof Grant Stewart
University Of Cambridge
1300 - 1400
Lunch
1400 - 1420
Radiation Oncology-The role of SBRT in Renal Oligometastases
Dr Sophia Kamran
Harvard Medical School
1420 - 1440
Living Well With and Beyond Cancer and the Future
Prof Suzanne Chambers
Australian Catholic University, Brisbane
1440- 1500
Genomic Characteristics of Metastatic Urothelial Carcinoma
Dr Min Yuen Teo
MSKCC, New York
1500 - 1520
Kidney Cancer in 2025 and 2050 – New Horizons and Wild Predictions
Mr Thomas Walton
Nottingham City Hospital
1520 - 1540
Updates in High Risk Non-Muscle Invasive Bladder Cancer
Dr Girish Kulkarni
Princess Margaret Cancer Center, Toronto
1540 – 1615
Panel Discussion- Prostate
1615
End of Proceedings